

INOVIO PHARMACEUTICALS, INC.

Form 8-K

March 10, 2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934**

Date of Report

(Date of earliest event reported)

March 5, 2014

INOVIO PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

**Delaware
(State or other jurisdiction)**

**001-14888
(Commission)**

**33-0969592
(I.R.S. Employer)**

of incorporation)

File Number)

Identification No.)

1787 Sentry Parkway West

Building 18, Suite 400

Blue Bell, Pennsylvania

(Address of principal executive offices)

Registrant's telephone number, including area code: (267) 440-4200

19422

(Zip Code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01. Entry into Material Definitive Agreement.

On March 5, 2014, we entered into an office lease (the Lease) with a publically owned real estate investment trust, located in Plymouth Meeting, Pennsylvania. We expect to occupy the space commencing in the third quarter of 2014. The initial term of the lease is eleven and one-half years. We intend to use the facility for office purposes.

The base rent adjusts periodically throughout the term of the Lease, with payments ranging from zero to \$58,163.56 per month. In addition, we will pay the landlord our share of operating expenses and property management fee. We have paid the landlord a security deposit of \$48,668.67.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant.

We will have contractual payment obligations under the Lease as described in 1.01 of this Form 8-K report, which description is incorporated into this item by reference.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INOVIO PHARMACEUTICALS, INC.

By: /s/Peter Kies
Peter Kies,

Chief Financial Officer

Date: March 10, 2014